LY 228729

Drug Profile

LY 228729

Latest Information Update: 22 Aug 2001

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antiemetics; Anxiolytics; Ergolines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Nausea and vomiting
  • Discontinued Anxiety disorders

Most Recent Events

  • 22 Aug 2001 No-Development-Reported for Emesis in USA (Unknown route)
  • 13 Feb 1998 Preclinical development for Emesis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top